Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Remifentanil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 14/20 | 0.69 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.89 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.69 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remifentanil SCHEMBL4376353 | 0.94 | CACNA1C (0.85) | CACNA1COPRM1OPRD1OPRK1OPRL1 | |
| Remifentanil SCHEMBL36652 | 0.94 | CACNA1C (1.00) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL17874058 | 0.94 | CACNA1C (1.00) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL29846323 | 0.93 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL3711219 | 0.93 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL3423820 | 0.93 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL41242 | 0.93 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL27828413 | 0.92 | CACNA1C (0.96) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL1649640 | 0.92 | CACNA1C (0.96) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL8446617 | 0.89 | CACNA1C (0.90) | CACNA1COPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121029-A2 | PRODRUGS AND METHODS OF MAKING AND USING THE SAME | Neurogesx, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080318905-A1 | Prodrugs and methods of making and using the same | NEUROGESX, INC. | 2008-12-25 | — | — | US | disclosed |
| WO-2008070149-A2 | PRODRUGS AND METHODS OF MAKING AND USING THE SAME | NEUROGESX, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318905-A1 | Prodrugs and methods of making and using the same | NAPEPLD, CES2, MTAP | OPRM1 11/4885CACNA1C 1922/4885OPRD1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.